Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00327743
Status:
COMPLETED
Last Update Posted:
2016-05-18
First Post:
2006-05-04
Brief Title:
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Dose-escalating Multicenter Single Arm Open-Label Study of XRP9881 in Combination With Capecitabine Xeloda in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this phase I-II clinical research study is to find the highest safe dose of XRP9881 and capecitabine that can be given in combination in the treatment of metastatic breast cancer in patients who have been previously treated by taxanes and anthracyclines The safety and effectiveness of this combination will also be studied Patients participating in the study will be asked to give additional blood samples to look at the level of study drugs in the blood
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT2006-006474-21 | None | None | None |